P/B
1,3
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
$350.2M
Market Cap • 9/18/2026
2020
(6 years)
Founded
2025
(1 year ago)
IPO
NYSE
Listing Exchange
United States
Country
Valuation
P/S
35
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
12,2
EPS
—
Market Cap
Market Cap
350,2M
EV
157,1M
EV/Revenue
15,7
EV/EBITDA
-1,6
EV/EBIT
-1,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-45,1%
Total Yield
-45,1%
Payout
0%
Retained Earnings
-275M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
837,7%
Capex/Revenue
5%
Capex/D&A
32,6%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
3,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,9
Debt/Equity
0%
Current Ratio
11,7
Quick Ratio
11,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!